Indicated for: hematologic malignancies
Route of administration: infusion
Substance: bendamustine (alkylating antineoplastic agent)
ATC: L01AA09 (Antineoplastic and immunomodulating agents | Alkylating agents | Nitrogen mustard analogues)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Bendamustine is a medication used for the treatment of certain types of cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. It is an alkylating chemotherapeutic agent that interferes with the DNA of cancer cells, inhibiting cell division and causing cell death.
The medication is administered via intravenous infusion, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer and the patient's response.
Common side effects include nausea, vomiting, fatigue, decreased blood cell counts, and infections. In rare cases, more severe adverse effects such as liver failure or severe allergic reactions may occur.
Bendamustine is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.